Abstract: Objective :To investigate the effect of neoadjuvant chemotherapy on the stage ovarian carcinoma. Methods :Retrospective analysis of 37 patients with stage ovarian carcinoma treated between 1998 and 2001, of which the serum CA125 values were 750u/ml on the admission. Among these patients, 15 cases were treated with neoadjuvant chemotherapy followed by surgery (NACT group),whereas 22 cases were treated conventionally with primary surgery (Conventional group). Other 23 pabents were served as Low CA125 group, of which the serum CA125 value were <750u/ml. The three groups were compared with respect optimal tumor resection rates and progression-free survival (PFS) and overall survival (OS). Results :The optimal surgery rate in the patient group receiving neoadjuvantchemotherapy (67%) was significantly higher than the conventional group (27%), and was similar with the Low CA125 group (65%). The median PFS of NACT group and conventional group were 121weeksand 68weeks,respectively (P=0.3001). The median OS of NACT group and conventional group were weeks and 157 weeks,respectively (P=0.357), and the NACT group had a trend prolong survival.with no statistical significance. The amount of residual disease COX model analysis. Conclusions :The patients of stage ovarian was the only prognostic factor bycarcinoma with CA125750u/ml, if receiving NACT, could have better surgery result, and have a trend prolong survival, especially for the optimal surgery patients after NACT.